Novel peptides and their applications
The novel peptide GV2001 addresses the instability of GV1001 by enhancing stability and efficacy in treating Alzheimer's disease and age-related macular degeneration through reduced amyloid-beta deposition and inflammatory cytokines, providing prolonged therapeutic effects.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- GEMBUCKS & FROG CO LTD
- Filing Date
- 2024-06-21
- Publication Date
- 2026-07-01
AI Technical Summary
Current treatments for Alzheimer's disease and age-related macular degeneration, particularly dry AMD, are inadequate, with existing drugs like GV1001 having stability issues and short half-lives, necessitating frequent administration, and there is a need for more effective and stable therapeutic options.
Development of a novel peptide, GV2001, with enhanced stability and therapeutic effects, formulated as pharmaceutical compositions and health functional foods to reduce amyloid-beta deposition and inflammatory cytokines, and target retinal pigment epithelial cell degeneration.
GV2001 demonstrates superior stability and efficacy in reducing amyloid-beta plaques, inflammatory cytokines, gliosis, and retinal pigment epithelial cell degeneration, offering prolonged therapeutic benefits with lower doses.
Smart Images
Figure 2026521698000001_ABST